Not really mate, we just have to wait until late October and take a look at SQM and AKE's contract pricing. Despite many commentators insisting that contract prices are way higher than spot, AKE received $38k per tonne for Q2 and SQM received $34k per tonne for Q2. These figures are largely in line (or slightly lower) than the spot prices throughout Q2.
I expect Q3 lithium carbonate prices to be US$30-32k; however, if the spot price keeps falling we may see contract pricing drop into the $27-$30K range. I look forward to checking out the Q3 contract pricing in about six weeks' time so we can dispel some of these contract pricing myths.
And at this stage we have no idea where the offtake will go. Many are convinced that it will be Japanese or Korean just because that's where samples went three years ago. But who knows really? Maybe they were some of the parties that couldn't offer the "best deal". It's possible that the preferred offtake partner is Chinese, North American or European. We'll just have to wait and see.
- Forums
- ASX - By Stock
- AGY
- Li-related News/Articles/Reports
Li-related News/Articles/Reports, page-5377
-
- There are more pages in this discussion • 3,556 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AGY (ASX) to my watchlist
|
|||||
Last
8.5¢ |
Change
-0.008(8.60%) |
Mkt cap ! $123.7M |
Open | High | Low | Value | Volume |
9.0¢ | 9.3¢ | 8.5¢ | $362.9K | 4.093M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 459867 | 8.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.7¢ | 93664 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 459867 | 0.085 |
3 | 99873 | 0.084 |
4 | 169062 | 0.083 |
3 | 336585 | 0.082 |
2 | 114691 | 0.081 |
Price($) | Vol. | No. |
---|---|---|
0.087 | 93664 | 1 |
0.088 | 232558 | 1 |
0.089 | 69615 | 2 |
0.090 | 91167 | 2 |
0.091 | 52101 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AGY (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online